The Janssen COVID-19 vaccine is now limited to certain individuals ages 18 and up after the U.S. Food and Drug Administration downgraded its emergency use authorization.
Novavax shared positive initial results from the Phase I/II clinical study of the company’s proposed combination vaccine for COVID-19.
Drugmaker Shionogi applied for approval to make and sell the company’s oral COVID-19 treatment in Japan, the firm said on February 25.
The world’s first medical trial authorized to deliberately expose participants to the coronavirus is seeking more volunteers as it steps up efforts to help develop better vaccines.
Temps are falling and so is investor cash as BioSpace reviewed which biotech companies are scooping up the dollars.
Coronavirus infection during pregnancy does not appear to affect infants’ brain function, but the pandemic itself may be having an impact, a study published on January 4 in JAMA Pediatrics suggests. Additionally, new laboratory research found the coronavirus can directly damage the kidneys by initiating a cascade of molecular events that leads to scarring.
A U.S. appeals court on December 17 reinstated a nationwide vaccine-or-testing COVID-19 mandate for large businesses, which covers 80 million American workers, prompting opponents to rush to the Supreme Court to ask it to intervene.
A research team at the University of North Carolina – Chapel Hill (UNC) and Duke University identified an antibody that attacks SARS-CoV-2, the virus that causes COVID-19, but also its variants and other types of coronaviruses.
The Delta variant of the coronavirus does not appear to cause more severe disease in children than earlier forms of the virus, a UK study suggests. Another study found that in Covid-19 survivors, important components of the body’s immune response called memory B cells continue to evolve and get stronger for at least several months, producing highly potent antibodies that can neutralize new variants of the virus.
The effectiveness of the Pfizer Inc./BioNTech SE vaccine in preventing infection by the coronavirus dropped to 47 percent from 88 percent six months after the second dose, according to data published on Oct. 4 that U.S. health agencies considered when deciding on the need for booster shots.